Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 204 citing Charbonnel: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added.... (0.11 sec) 

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and …

- wanfang.gov.tw [DOC] 
RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc
You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ...
Cited by 248 - Related articles - BL Direct - All 8 versions

Biology of incretins: GLP-1 and GIP

- rh.dk [PDF] 
LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier
This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ...
Cited by 179 - Related articles - All 25 versions

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with …


MA Nauck, G Meininger, D Sheng, L … - Diabetes, Obesity …, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 133 - Related articles - All 7 versions

Finding new treatments for diabetes--how many, how fast... how good?


DM Nathan - New England Journal of Medicine, 2007 - content.nejm.org
Two modern-day epidemics, HIV–AIDS and type 2 diabetes mellitus, have inspired impassioned
calls for more effective interventions. In the 1980s, the rapid spread of HIV, with its associated
severe, acute illness and high mortality, prompted activist groups and others to call for the ...
Cited by 113 - Related articles - BL Direct - All 7 versions

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 …

- diabetesjournals.org
BJ Goldstein, MN Feinglos, JK Lunceford, J … - Diabetes Care, 2007 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind,
placebo-controlled, parallel-group study, 1,091 patients with type 2 diabetes and A1C
7.5–11% were randomized to one of six daily treatments: sitagliptin 100 mg/metformin ...
Cited by 96 - Related articles - BL Direct - All 9 versions

[PDF] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with …


K Hermansen, M Kipnes, E Luo, D Fanurik, H … - Diabetes Obes …, 2007 - januvia.com
Thank you for your interest in the enclosed reprint, “Efficacy and Safety of the Dipeptidyl
Peptidase-4 Inhibitor, Sitagliptin, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled
on Glimepiride Alone or on Glimepiride and Metformin" by K. Hermansen et al, as ...
Cited by 76 - Related articles - View as HTML - All 5 versions

Dipeptidyl peptidase-4 inhibitors

- diabetesjournals.org
B Ahrén - Diabetes Care, 2007 - Am Diabetes Assoc
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like
peptide-1 (GLP-1). Since GLP-1–based therapy is a promising novel treatment of type 2
diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors ...
Cited by 51 - Related articles - BL Direct - All 11 versions

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical …

- diabetesjournals.org
DJ Drucker - Diabetes care, 2007 - Am Diabetes Assoc
Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a membrane-anchored cell
surface peptidase that transmits intracellular signals via a short intracellular tail and as a second
smaller soluble form present in the circulation. DPP-4 cleaves a large number of ...
Cited by 42 - Related articles - BL Direct - All 11 versions

The role of {alpha}-cell dysregulation in fasting and postprandial hyperglycemia in …

- endojournals.org
BE Dunning, JE Gerich - Endocrine reviews, 2007 - Endocrine Soc
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts
to optimize methods for the purification of insulin. The hyperglycemic substance was named
"glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide ...
Cited by 32 - Related articles - BL Direct - All 5 versions

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients …


I Raz, Y Chen, M Wu, S Hussain, KD … - Current Medical …, 2008 - informahealthcare.com
Objective: The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an
add-on to metformin therapy in patients with moderately severe (hemoglobin A1c ≥8.0% and
≤11.0%) type 2 diabetes mellitus (T2DM). Research design and methods: This was a ...
Cited by 33 - Related articles - BL Direct - All 4 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google